PENG Jumps 24.3% on Raised FY27 Outlook; CLF, SEZL Also Surge
Penguin Solutions (PENG) gained 24.3% to $76.28 after analysts hiked price targets to as high as $100 on a Q4 beat and a raised fiscal 2027 EPS outlook of $4.45. Cleveland-Cliffs (CLF) jumped 14.7% to $12.98 after Wells Fargo upgraded the stock to Overweight with a $14 target. Sezzle (SEZL) rose 14.0% to $128.64, and Rezolute (RZLT) added 12.7% to $4.87 on an FDA pre-BLA meeting recommendation, while JBS gained 11.2% to $12.98.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| PENG | Technology | 2026-10-02 | N/A | +24.3% |
| CLF | Basic Materials | 2026-10-02 | +6.8pp | +14.7% |
| SEZL | Financial | 2026-10-06 | N/A | +14.0% |
| RZLT | Healthcare | 2026-10-06 | +1.7pp | +12.7% |
| JBS | Consumer Defensive | 2026-10-02 | +1.4pp | +11.2% |
Why did PENG stock jump in October 2026?
PENG jumped 24.3% (from $61.36 to $76.28) after analysts raised its next-year EPS growth estimate to 29.2% on October 2 and later hiked targets as high as $100 on October 7.
The rally was triggered by a fiscal Q4 beat on October 7: revenue rose 68% to $567 million and non-GAAP EPS came in at $1.00, topping the $0.77 consensus. Management raised its fiscal 2027 outlook to $2.43 billion in sales and $4.45 in non-GAAP EPS, well above consensus of $2.21 billion and $3.38. Rosenblatt raised its target to $100 from $80, saying the results pulled its bull case forward by a full year, while Stifel and Needham noted Integrated Memory revenue surged 158% year over year.
PENG EPS revision history → · Screener snapshot from 2026-10-02 →
FAQ: PENG
Why did PENG stock jump on October 7, 2026?
PENG jumped 24.3% to $76.28 after reporting record fiscal Q4 revenue of $567 million, up 68%, and EPS of $1.00, beating consensus by $0.23. Analysts also raised price targets to as high as $100 following the raised fiscal 2027 outlook.
Is PENG a buy after the rally?
Rosenblatt maintained a Buy rating with a $100 target, implying further upside, but Barclays kept an Underweight rating with a $60 target, citing expected gross margin pressure. The forward P/E is above its five-year average, suggesting elevated expectations.
What is PENG's EPS growth estimate for next year?
PENG's next-year EPS growth estimate is 29.2%, and the company guided fiscal 2027 non-GAAP EPS to $4.45, representing about 55% growth over fiscal 2026.
Why did CLF stock jump in October 2026?
CLF jumped 14.7% (from $11.32 to $12.98) after analysts revised its next-year EPS growth estimate from 523.5% to 530.4% on October 2 and Wells Fargo upgraded the stock to Overweight on October 6.
Wells Fargo raised its price target to $14 from $12, arguing that Wall Street is underestimating the steelmaker's 2027 earnings potential. The bank projects $2.65 billion in 2027 EBITDA, materially above consensus, even assuming benchmark hot-rolled coil prices normalize to ~$1,000 per short ton from recent levels near $1,250. The upgrade also cited the Stelco bridge, where Canadian HRC prices have surged to roughly $1,100 per short ton from under $700, creating an estimated $800 million annualized benefit.
CLF EPS revision history → · Screener snapshot from 2026-10-02 →
FAQ: CLF
Why did CLF stock jump on October 6, 2026?
CLF jumped 14.7% to $12.98 after Wells Fargo upgraded the stock to Overweight and raised its price target to $14 from $12, citing underestimated 2027 EBITDA potential. The upgrade followed a 6.8 percentage point upward EPS estimate revision on October 2.
Is CLF a buy after the upgrade?
Wells Fargo sees upside to $14, implying about 8% from the current price, based on a 6x 2027 EV/EBITDA multiple. The bull case hinges on $2.65 billion in 2027 EBITDA, above FactSet consensus, and a Stelco bridge benefit of $800 million annualized.
What is CLF's EPS growth estimate for next year?
CLF's next-year EPS growth estimate was revised to 530.4% on October 2, up from 523.5%, reflecting expectations of a sharp earnings rebound in 2027.
Why did SEZL stock jump in October 2026?
SEZL jumped 14.0% (from $112.84 to $128.64) after analysts raised its next-year EPS growth estimate to 27.3% on October 6 and the company announced its Q3 earnings date on October 8.
Sezzle will release third-quarter 2026 results on November 4, with management set to participate in five investor conferences through December, including the BMO Financials Conference and Citi's FinTech Conference. The stock is the best performer among consumer finance peers in 2026, gaining more than 77% year to date, even as TD Cowen lowered its price target on the stock as part of a broader Q3 preview. The EPS revision and conference schedule have reinforced expectations for continued growth in the buy-now-pay-later sector.
SEZL EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: SEZL
Why did SEZL stock jump on October 8, 2026?
SEZL jumped 14.0% to $128.64 after the company announced its Q3 2026 earnings date and upcoming investor conferences, following a next-year EPS growth estimate revision to 27.3% on October 6. The stock has gained over 77% year to date, the best among consumer finance peers.
Is SEZL a buy after the recent rally?
Sezzle is the top-performing consumer finance stock in 2026, up over 77%, but TD Cowen recently lowered its price target as part of a Q3 preview. Investors will watch the November 4 earnings report for confirmation of growth trends.
What is SEZL's EPS growth estimate for next year?
SEZL's next-year EPS growth estimate is 27.3%, as of the October 6 revision. The company has not yet reported Q3 2026 results, which are due on November 4.
Why did RZLT stock jump in October 2026?
RZLT jumped 12.7% (from $4.32 to $4.87) after analysts raised its next-year EPS growth estimate from 25.6% to 27.3% on October 6, following an FDA update on October 5.
The FDA recommended a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism, despite the Phase 3 sunRIZE study missing its primary and key secondary endpoints. The agency reviewed additional glucose-monitoring data before suggesting the meeting, which is a precursor to a potential Biologics License Application. The open-label extension remains ongoing, with patients continuing Ersodetug, suggesting possible lasting clinical benefit.
RZLT EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: RZLT
Why did RZLT stock jump on October 5, 2026?
RZLT jumped 12.7% to $4.87 after the FDA recommended a pre-BLA meeting for Ersodetug, even though the Phase 3 sunRIZE study missed its primary endpoints. The FDA reviewed additional glucose-monitoring data before making the recommendation.
Is RZLT a buy after the FDA update?
The FDA's recommendation for a pre-BLA meeting keeps a potential regulatory filing on track, but the Phase 3 miss remains a significant risk. The next catalyst is the pre-BLA meeting itself; no date has been disclosed.
What is RZLT's EPS growth estimate for next year?
RZLT's next-year EPS growth estimate is 27.3%, up 1.7 percentage points from 25.6%, as revised on October 6.
Why did JBS stock jump in October 2026?
JBS jumped 11.2% (from $11.67 to $12.98) after analysts raised its next-year EPS growth estimate from 81.7% to 83.0% on October 2, with no company-specific news in the window.
The upward revision reflects improving margin expectations for global protein producers, supported by tight beef supply and resilient consumer demand. JBS, the world's largest meat processor, benefits from diversified operations across beef, pork, and poultry, which cushion commodity volatility. The stock's gain since detection has outpaced the broader Consumer Defensive sector, signaling that the earnings revision is being validated by price action.
JBS EPS revision history → · Screener snapshot from 2026-10-02 →
FAQ: JBS
Why did JBS stock jump on October 2, 2026?
JBS jumped 11.2% to $12.98 after analysts raised its next-year EPS growth estimate from 81.7% to 83.0% on October 2. No company-specific news was released, so the move reflects sector-wide margin optimism.
Is JBS a buy after the recent gain?
The EPS estimate revision suggests improving earnings prospects, but without fresh company news, the rally may be driven by sector momentum. Investors should watch for the next earnings report for confirmation.
What is JBS's EPS growth estimate for next year?
JBS's next-year EPS growth estimate is 83.0%, up 1.4 percentage points from 81.7%, as revised on October 2.
Today's batch of double-digit gainers—led by PENG's 24.3% surge—shows that upward EPS estimate revisions, when paired with analyst target hikes or regulatory catalysts, are being aggressively rewarded despite broader market volatility. The moves in CLF, SEZL, RZLT, and JBS highlight that earnings revisions across technology, materials, financials, healthcare, and consumer defensives are being validated by price action, suggesting a market that is still willing to pay for growth when guidance improves.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →